title: Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer.
abstract: Metabolic imaging may contribute to a better knowledge of the biology of breast cancer and to new drugs development. Positron emission tomography (PET) with the radiolabeled glucose analogue 2- [18F]-fluorodeoxyglucose (18F-FDG) allows quantitative assessment of glucose utilization in tumor tissue. This technique utilizes a class of radioisotopes that decay by emitting a positron. The positron travels a short distance (1 mm) before interacting with an electron in what is called an annihilation reaction. This results in the creation of two high-energy photons that are emitted in opposite directions. The PET scanner detects such annihilation radiations and produces a three-dimensional picture of the distribution of the radiolabeled tracer. 18F-FDG PET has currently a limited role in breast cancer, due to its low sensitivity that makes it not recommended in most of the cases, especially in early disease. Potentially, the most useful application of PET/CT is monitoring the changes in 18F-FDG uptake during chemotherapy in order to detect an early response to treatment. In fact, while morphological changes due to effective chemotherapy are not detectable until late in the course of treatment, metabolic changes generally occur earlier. In this paper, we summarize the current and future applications of PET in the management of breast cancer.
authors.affiliation: Division of Medical Oncology, Galliera Hospital, Via Volta n. 6, 16125, Genoa, Italy. alessandra.gennari@galliera.it
authors.forename: Alessandra
authors.initials: A
authors.lastname: Gennari
authors.forename: Arnoldo
authors.initials: A
authors.lastname: Piccardo
authors.forename: Vania
authors.initials: V
authors.lastname: Altrinetti
authors.forename: Davide
authors.initials: D
authors.lastname: Corradengo
authors.forename: Giampiero
authors.initials: G
authors.lastname: Villavecchia
authors.forename: Andrea
authors.initials: A
authors.lastname: De Censi
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D042241:Early Diagnosis; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009367:Neoplasm Staging / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
references.citation: Nat Rev Cancer. 2006 May;6(5):409-14
references.pmid: 16633367
references.citation: J Nucl Med. 2010 May;51(5):761-7
references.pmid: 20395337
references.citation: J Nucl Med. 2008 Mar;49(3):480-508
references.pmid: 18287273
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Clin Breast Cancer. 2000 Jul;1(2):156-61; discussion 162-3
references.pmid: 11899654
references.citation: Radiographics. 2007 Oct;27 Suppl 1:S197-213
references.pmid: 18180227
references.citation: J Nucl Med. 2005 Jul;46(7):1144-50
references.pmid: 16000283
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1253-9
references.pmid: 15051773
references.citation: Breast Cancer Res Treat. 2007 Sep;105(1):87-94
references.pmid: 17268819
references.citation: Cancer. 2006 Dec 1;107(11):2545-51
references.pmid: 17063499
references.citation: JAMA. 1994 May 25;271(20):1587-92
references.pmid: 8182811
references.citation: Breast Cancer Res Treat. 2012 Jan;131(1):117-26
references.pmid: 21935602
references.citation: Breast Cancer Res Treat. 2012 Jan;131(2):357-69
references.pmid: 21960111
references.citation: Eur J Nucl Med. 1993 Nov;20(11):1063-9
references.pmid: 8287874
references.citation: Eur J Surg Oncol. 2012 Jan;38(1):31-7
references.pmid: 21937190
references.citation: Lancet. 1983 Sep 10;2(8350):613-6
references.pmid: 6136757
references.citation: J Clin Oncol. 1993 Nov;11(11):2101-11
references.pmid: 8229124
references.citation: Clin Pharmacol Ther. 2010 May;87(5):586-92
references.pmid: 20357763
references.citation: J Nucl Med. 2009 May;50 Suppl 1:122S-50S
references.pmid: 19403881
references.citation: J Comput Assist Tomogr. 1993 Jul-Aug;17(4):582-9
references.pmid: 8331230
references.citation: J Clin Oncol. 1995 Jun;13(6):1470-7
references.pmid: 7751894
references.citation: J Nucl Med. 1999 Oct;40(10):1623-9
references.pmid: 10520701
references.citation: AJR Am J Roentgenol. 2011 Aug;197(2):341-7
references.pmid: 21785079
references.citation: Radiographics. 2007 Oct;27 Suppl 1:S215-29
references.pmid: 18180228
references.citation: J Clin Oncol. 2010 Jul 1;28(19):3154-9
references.pmid: 20516453
references.citation: J Nucl Med. 1991 Aug;32(8):1526-31
references.pmid: 1869973
references.citation: AJR Am J Roentgenol. 2004 Aug;183(2):479-86
references.pmid: 15269044
references.citation: J Clin Oncol. 1998 Oct;16(10):3375-9
references.pmid: 9779715
references.citation: J Nucl Med. 2009 Oct;50(10):1666-75
references.pmid: 19759118
references.citation: Eur J Surg Oncol. 2011 Mar;37(3):187-98
references.pmid: 21269795